University of Southern California, Los Angeles, CA
Julia Stal , Serena Yi , Sally Cohen-Cutler , Phuong Gallagher , Afsaneh Barzi , Joel Milam , David R. Freyer , Heinz-Josef Lenz , Kimberly Ann Miller
Background: Clinical guidelines indicate that oncologists should discuss potential treatment-induced infertility with patients with reproductive potential. Due to tumor location and use of multimodal therapies, young adults with colorectal cancer (CRC) are at heightened risk for treatment-related infertility. Methods: An online, cross-sectional survey was administered in collaboration with a national patient advocacy organization for young adult CRC survivors (currently under age 50). Survivors were asked to indicate if a doctor had ever talked to them about potential problems with their ability to have children after treatment and if they banked eggs/embryos (females) or sperm (males) prior to their cancer therapy. Those who reported that they did not preserve fertility were asked to indicate why (not sure; I chose not to; I did not know this was an option; I wanted to, but could not afford it; and I wanted to, but my treatment would not allow it). Results: A total of 234 colon (N=86) or rectal (N=148) cancer survivors were included in the study (male [61.9%] and White [77.9%; table]). Most respondents were diagnosed with stage 2 cancer (55.8% colon, 61.6% rectal). Over half of male and female survivors reported that their doctor did not talk to them about problems with their ability to have children after treatment, and 75% did not bank eggs/embryos or sperm prior to their cancer therapy. Of those, over 20% endorsed ‘I wanted to, but could not afford it’ and over 20% endorsed ‘I did not know this was an option’. Conclusions: Most CRC survivors in this study reported never having a fertility discussion with their provider, suggesting that survivors are not receiving, or cannot recall, comprehensive and guideline-concordant cancer care. In addition, one-fifth were not aware of preservation options, suggesting potential healthcare and/or provider-level barriers to appropriate fertility counseling. Fertility preservation cost is another barrier to the appropriate delivery of care. Providers must ensure that patients receive timely fertility discussions covering options to preserve fertility to mitigate this late effect of cancer treatment to ensure optimal quality of life for CRC patients with reproductive potential.
Fertility preservation frequencies (N=234). | ||
---|---|---|
Gender | ||
Male | Female | |
Has a doctor ever talked to you about problems with your ability to have children after your treatment? | ||
Yes | 60 (41.38) | 35 (41.18) |
No | 81 (55.86) | 49 (57.65) |
Not Sure | 4 (2.76) | 1 (1.18) |
Did you bank eggs/embryos (female; sperm, male) prior to your cancer therapy? | ||
Yes | 30 (20.98) | 19 (22.35) |
No | 107 (74.83) | 64 (75.29) |
Not Sure | 6 (4.20) | 2 (2.35) |
If no (did not bank eggs/embryos or sperm), I decided not to because... | ||
I wanted to, but my treatment would not allow it | 9 (6.38) | 4 (4.82) |
I wanted to, but could not afford it | 31 (21.99) | 19 (22.89) |
I did not know this was an option | 33 (23.40) | 18 (21.69) |
I chose not to | 58 (41.13) | 38 (45.78) |
Not sure | 10 (7.09) | 4 (4.82) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Gastrointestinal Cancers Symposium
First Author: Dalia Kagramanov
2021 ASCO Annual Meeting
First Author: Eric Hess
2024 ASCO Annual Meeting
First Author: Lauren Victoria Ghazal
2023 ASCO Annual Meeting
First Author: Aryana Sepassi